EGFR gene mutation

5 clinical trials

Quick filters

Clinical trials for EGFR gene mutation

5 trials across Europe

See all trials →

Quick filters

5 Clinical trials

Endometrial cancer+18

Recruiting

InvestigationalNo placebo

Study on the Effectiveness and Safety of BAY 2927088 for Patients with Advanced Solid Tumors with HER2 Mutations

InvestigationalNo placebo

Denmark

Participants:18–64 years · 65+ years
Substances:Bay 2927088
Sponsor:Bayer AG

Contact Research Centre

EGFR gene mutation+1

Recruiting

InvestigationalNo placebo

Study on Patritumab Deruxtecan and Zirconium (89Zr) Patritumab Deruxtecan for Patients with Advanced EGFR Mutation Positive Lung Cancer

InvestigationalNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Patritumab Deruxtecan
Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Contact Research Centre

EGFR gene mutation+1

Not recruiting

Registered drugNo placebo

Study on the Effectiveness and Safety of BAY 2927088 Compared to Standard Treatment in Patients with Advanced Non-Small Cell Lung Cancer with HER2 Mutations

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Bay 2927088
Sponsor:Bayer AG

Contact Research Centre

EGFR gene mutation+1

Not recruiting

Registered drugNo placebo

Study on Amivantamab, Lazertinib, and Bevacizumab for Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer After Treatment Progression

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Amivantamab
Sponsor:ETOP IBCSG Partners Foundation

Contact Research Centre

EGFR gene mutation+1

Not recruiting

Registered drugNo placebo

Study of Osimertinib for Patients with EGFR-Mutated Non-Small Cell Lung Cancer

Registered drugNo placebo

Lithuania

Participants:18–64 years · 65+ years
Substances:Osimertinib
Sponsor:Vestre Viken HF

Contact Research Centre

See all trials →

EGFR gene mutation

Clinical trials for EGFR gene mutation

Endometrial cancer+18

Study on the Effectiveness and Safety of BAY 2927088 for Patients with Advanced Solid Tumors with HER2 Mutations

EGFR gene mutation+1

Study on Patritumab Deruxtecan and Zirconium (89Zr) Patritumab Deruxtecan for Patients with Advanced EGFR Mutation Positive Lung Cancer

EGFR gene mutation+1

Study on the Effectiveness and Safety of BAY 2927088 Compared to Standard Treatment in Patients with Advanced Non-Small Cell Lung Cancer with HER2 Mutations

EGFR gene mutation+1

Study on Amivantamab, Lazertinib, and Bevacizumab for Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer After Treatment Progression

EGFR gene mutation+1

Study of Osimertinib for Patients with EGFR-Mutated Non-Small Cell Lung Cancer

Filter the trials

Prefer not to search? Our Concierge searches the trials for you.